Dopamine transporter loss and clinical changes in MPTP-lesioned primates

Brain Res. 1999 Jun 19;832(1-2):184-7. doi: 10.1016/s0006-8993(99)01491-2.

Abstract

Single photon emission computed tomography (SPECT) and the dopamine (DA) transporter tracer, 2 beta-carboxymethoxy-3 beta-(4-iodophenyl)tropane ([123I]beta-CIT), were used to determine DA transporter density in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP)-lesioned monkeys with varying degrees of parkinsonism. The clinical stage of parkinsonism corresponded to SPECT measures of striatal DA transporter density suggesting that more severe parkinsonism was associated with a greater degree of dopaminergic terminal degeneration. These findings are similar to those reported earlier using positron emission tomography (PET) and the DA metabolism tracer, 6-[18F]fluoro-L-m-tyrosine (FMT), indicating that both are good methods for evaluating nigrostriatal degeneration in MPTP primate models.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Carrier Proteins / metabolism*
  • Dopamine Agents / toxicity*
  • Dopamine Plasma Membrane Transport Proteins
  • MPTP Poisoning*
  • Macaca mulatta
  • Membrane Glycoproteins*
  • Membrane Transport Proteins*
  • Nerve Tissue Proteins*
  • Parkinson Disease, Secondary / chemically induced
  • Parkinson Disease, Secondary / diagnostic imaging
  • Parkinson Disease, Secondary / metabolism*
  • Tomography, Emission-Computed
  • Tomography, Emission-Computed, Single-Photon

Substances

  • Carrier Proteins
  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Membrane Glycoproteins
  • Membrane Transport Proteins
  • Nerve Tissue Proteins